ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies

ANP Technologies® Inc receives Innovators Award from Delaware Bioscience Association

The U.S. Food and Drug Administration (FDA) has granted approval for ANP Technologies, Inc. and its partner to begin Phase I clinical trials with its first drug – nanoencapsulated paclitaxel.

U.S. Army Awarded ANP Technologies, Inc. a Continued ID/IQ Manufacturing contract for 2-plexed Toxin Handheld Assays

U.S. Army has awarded ANP Technologies, Inc. and its partner a contract for full-fielding of the NIDS® ACE sensor as part of the Army’s Environmental Sentinel Biomonitor (ESB) program.

ANP Awarded an Additional SBIR Phase III Contract to Further Develop its NIDS® ACE Sensor Platform for the U.S Army.

ANP and Federal Resources (FR) Secure Multi-Million Dollar Contract with U.S. Air National Guard to Support Rapid Detection of Biological Threats via ANP’s Nano Intelligent Detection System (NIDS®).

Department of Defense Awards ANP A Multi-Million Dollar Contract to Develop Nano-Antibody Therapeutics to Treat Ebola Infection

Department of Defense Award Water Monitoring Contract for Biotoxins to ANP

National Guard Selects ANP as Premier Solution

Evaluation and Optimization of a Commercial ELISA Kit for the Detection of Anitbodies to Polyetheylene Glycol (PEG) In Human Serum for Use In Support of Clinical Studies for PEGylated Therapeutic Drug

Comparison of In Vivo Efficacy of Nanoencapsulated Paclitaxel with Taxol and Abraxane

Biotech Firms Need Innovation Strategies

St. georges tech students ask how safe is our produce

Global Delaware Success Stories - ANP Technologies